Skip to content
Library/For Energy/HGH (Somatotropin)
FDA Approved⚠ WADA Banned+2 more

HGH (Somatotropin)

Recombinant human growth hormone. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 14 minEvidence ●●●●●Citations 60

Free — puts HGH (Somatotropin) on your decision board.

The HGH (Somatotropin) Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
FDA
Class
WADA Banned
Evidence
5/ 5●●●●●
FDA approval (Humatrope)
1987
Approved indications (US)
WADA
Read this if
  • you have diagnosed adult growth hormone deficiency and your endocrinologist is talking about Humatrope
  • a "hormone optimization clinic" offered you HGH for $1,500/month and you want to know what you're signing
  • you've read the Rudman 1990 paper and want to know what the follow-up data actually showed
Skip this if
  • you're a healthy adult expecting "anti-aging" — the trial data doesn't support that
  • you have active malignancy, retinopathy, or severe insulin resistance
  • you're shopping by cap color ("blue-top," "yellow-top") — that's marketing on a counterfeit kit, not a purity signal
  • you're not okay with the federal-law angle on off-label HGH distribution
First 90 days · HGH (Somatotropin)
Weeks 1–2
Sleep depth shifts within days for the GH-secretagogue class (CJC, ipamorelin, sermorelin, hexarelin). If sleep hasn't deepened by week 2, the rest of the protocol probably won't move either.
Weeks 4–8
Subjective recovery and energy improvements. Body composition shifts modestly — slight muscle gain, slight fat loss if diet allows.
Week 12 — decide
Bloodwork: IGF-1 is the objective check. If IGF-1 hasn't moved, the protocol isn't working at this dose. Side effect bookkeeping: water retention, joint stiffness, any glucose changes.
Quit if
  • IGF-1 climbs above ~300 ng/mL (cancer-risk territory at the upper end).
  • Significant water retention or new carpal-tunnel-style symptoms.
  • New or worsening insulin resistance (fasting glucose creep).
  • 12 weeks with no IGF-1 movement and no subjective change.
Identity

What it is.

HGH is recombinant human growth hormone — the actual 191-amino-acid hormone the pituitary makes, manufactured in genetically engineered cell lines. Sold under brand names like Genotropin, Humatrope, Norditropin, Omnitrope. It's been on the market since 1985.

It's the reference compound for this whole category. Every secretagogue (ipamorelin, CJC-1295, sermorelin, MK-677) is trying to indirectly raise the same thing HGH directly is.

for a specific list: pediatric growth-hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease in children, idiopathic short stature, and adult growth-hormone deficiency (AGHD) confirmed by stimulation testing. That last category is the legitimate adult use.

WADA-banned. Selling HGH for off-label distribution (anti-aging, athletic use, body comp) without an indication is a federal crime under 21 USC §333(e) — the Anabolic Steroid Control Act of 1990 carved HGH out specifically. It is *not* a Schedule III controlled substance; the federal restriction is a standalone FDA-distribution felony.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what HGH (Somatotropin) actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19
Mechanism

Mechanism.

Mechanism · in the HGH (Somatotropin) report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19
Evidence

Evidence. What we actually know in humans.

Evidence · in the HGH (Somatotropin) report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19
Human-Evidence Factbox
FDA approval (Humatrope)
1987
Approved indications (US)
$19
List price (brand)
$19
Anti-aging claim validated
$19
"Blue-top vs yellow-top" means
$19
Dose

Dose. The actual protocol.

Dose · in the HGH (Somatotropin) report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the HGH (Somatotropin) report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19
Safety

Safety. Side effects.

Safety · in the HGH (Somatotropin) report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19
Editorial Position

Editorial position.

Editorial Position · in the HGH (Somatotropin) report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19
Citations

Citations.

  1. 01Deal CL, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. The Journal of clinical endocrinology and metabolism. 2022;107(7):e2717-e2728. PMID: 35405011.
  2. 02Thornton PS, et al. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. The Journal of clinical endocrinology and metabolism. 2021;106(11):3184-3195. PMID: 34272849.
  3. 03Webster R, et al. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica; the fate of foreign compounds in biological systems. 2008;38(10):1340-51. PMID: 18802875.
  4. 04Mehta A, et al. The use of somatropin (recombinant growth hormone) in children of short stature. Paediatric drugs. 2002;4(1):37-47. PMID: 11817985.
  5. 05Calzada-León R. [Use of recombinant Human Growth Hormone (rHGH)]. Revista medica del Instituto Mexicano del Seguro Social. 2017;55(2):196-213. PMID: 28296370.
+Show all 60 citations
  1. 06Pricci F, et al. Somatropin therapy in italian adults with growth hormone deficiency. BMC endocrine disorders. 2022;22(1):52. PMID: 35241041.
  2. 07Atkinson HF, et al. Effects of Recombinant Human Growth Hormone for Osteoporosis: Systematic Review and Meta-Analysis. Canadian journal on aging = La revue canadienne du vieillissement. 2017;36(1):41-54. PMID: 28069090.
  3. 08Phung OJ, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics. 2010;126(5):e1211-26. PMID: 20921071.
  4. 09Riaz M, et al. Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2024;34(8):932-935. PMID: 39113512.
  5. 10Kamrani S, et al. Spectroscopic analysis of recombinant human growth hormone in the presence of sucrose and trehalose. Biotechnology and applied biochemistry. 2023;70(4):1543-1553. PMID: 36807340.
  6. 11Lamb YN. Lonapegsomatropin: Pediatric First Approval. Paediatric drugs. 2022;24(1):83-90. PMID: 34709591.
  7. 12Mantzoros CS, et al. Whither recombinant human growth hormone?. Annals of internal medicine. 1996;125(11):932-4. PMID: 8967675.
  8. 13Burgess E, et al. Use of recombinant human growth hormone in HIV-associated lipodystrophy. Current opinion in infectious diseases. 2005;18(1):17-24. PMID: 15647695.
  9. 14Yin MT, et al. Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity. Expert review of anti-infective therapy. 2005;3(5):727-38. PMID: 16207164.
  10. 15Hardin DS, et al. Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers. Clinical pediatrics. 2007;46(4):279-86. PMID: 17475983.
  11. 16Gnacińska M, et al. Metabolic consequences of recombinant human growth hormone therapy in patients with Turner syndrome. Pediatric endocrinology, diabetes, and metabolism. 2023;29(1):16-21. PMID: 36734396.
  12. 17Stevens A, et al. Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature. Reviews in endocrine & metabolic disorders. 2021;22(1):135-143. PMID: 33712998.
  13. 18Pawlikowska-Haddal A. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency. Expert opinion on biological therapy. 2013;13(6):927-32. PMID: 23662811.
  14. 19Linglart A, et al. Long-acting growth hormone in the management of GHD in France. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2024;31(6):357-364. PMID: 39030125.
  15. 20Dos Santos JBR, et al. TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation. Expert opinion on drug delivery. 2022;19(1):1-7. PMID: 34996331.
  16. 21Chen S, et al. The Effects of Genetic Polymorphism on Treatment Response of Recombinant Human Growth Hormone. Current drug metabolism. 2018;19(14):1159-1167. PMID: 29219047.
  17. 22Shi Y, et al. Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls. Frontiers in endocrinology. 2022;13:1085385. PMID: 36589818.
  18. 23Henwood MJ, et al. Expanded spectrum of recombinant human growth hormone therapy. Current opinion in pediatrics. 2002;14(4):437-42. PMID: 12130909.
  19. 24Rivera-Hernández A, et al. [Somatropin and final height in Mexican paediatric population with growth hormone deficiency]. Andes pediatrica : revista Chilena de pediatria. 2022;93(4):496-503. PMID: 37906847.
  20. 25Saenger P. Ten years of biosimilar recombinant human growth hormone in Europe. Drug design, development and therapy. 2017;11:1505-1507. PMID: 28553081.
  21. 26Iglesias P, et al. Clinical applications of recombinant human growth hormone in adults. Expert opinion on pharmacotherapy. 1999;1(1):97-107. PMID: 11249568.
  22. 27Pan H, et al. [Safety considerations for the clinical application of recombinant human growth hormone]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2024;26(5):444-449. PMID: 38802902.
  23. 28Wanke C. Editorial comment: use of recombinant human growth hormone for wasting--questions for clinical practice. The AIDS reader. 2005;15(6):309. PMID: 15962454.
  24. 29Dyrka K, et al. Biological effects of recombinant human growth hormone therapy on metabolism in children with growth hormone deficiency: a review. Journal of pediatric endocrinology & metabolism : JPEM. 2025;38(8):796-806. PMID: 40320660.
  25. 30Deijen JB, et al. Impaired quality of life in hypopituitary adults with growth hormone deficiency : can somatropin replacement therapy help?. Treatments in endocrinology. 2006;5(4):243-50. PMID: 16879003.
  26. 31Chen J, et al. Polyethylene glycol recombinant human growth hormone in Chinese prepubertal slow-growing short children: doses reported in a multicenter real-world study. BMC endocrine disorders. 2022;22(1):201. PMID: 35945517.
  27. 32Zhang J, et al. Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review. Scientific reports. 2025;15(1):26746. PMID: 40702077.
  28. 33Svensson J, et al. Long-term efficacy and safety of somatropin for adult growth hormone deficiency. Treatments in endocrinology. 2003;2(2):109-20. PMID: 15871547.
  29. 34Zaky DA, et al. Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module. International immunopharmacology. 2021;101(Pt B):108370. PMID: 34794887.
  30. 35van Dam PS. Somatropin therapy and cognitive function in adults with growth hormone deficiency : a critical review. Treatments in endocrinology. 2006;5(3):159-70. PMID: 16677058.
  31. 36He C, et al. Detection of doping with recombinant human growth hormone. Bioanalysis. 2009;1(5):953-65. PMID: 21083065.
  32. 37Iglesias P, et al. Recombinant human growth hormone therapy in adult dialysis patients. The International journal of artificial organs. 2000;23(12):802-4. PMID: 11197738.
  33. 38Miccoli M, et al. Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis. Hormone research in paediatrics. 2016;86(1):27-34. PMID: 27355624.
  34. 39Watson SE, et al. Recent updates on recombinant human growth hormone outcomes and adverse events. Current opinion in endocrinology, diabetes, and obesity. 2013;20(1):39-43. PMID: 23183360.
  35. 40Puustinen L, et al. Recombinant human growth hormone treatment after liver transplantation in childhood: the 5-year outcome. Transplantation. 2005;79(9):1241-6. PMID: 15880078.
  36. 41Saavedra SL, et al. Single step recombinant human growth hormone (rhGH) purification from milk by peptide affinity chromatography. Biotechnology progress. 2018;34(4):999-1005. PMID: 29693323.
  37. 42Geffner ME, et al. Use of recombinant human growth hormone in children with thalassemia. Hormone research. 2009;71 Suppl 1:46-50. PMID: 19153505.
  38. 43Zhao J, et al. Effect of recombinant human growth hormone plus vitamin D on development and lipid metabolism in children with growth hormone deficiency. Biotechnology & genetic engineering reviews. 2024;40(3):2960-2970. PMID: 37066983.
  39. 44Arcasoy A, et al. Recombinant human growth hormone treatment in children with thalassemia major. Pediatrics international : official journal of the Japan Pediatric Society. 1999;41(6):655-61. PMID: 10618886.
  40. 45Ji Y, et al. Effect analysis of recombinant human growth hormone therapy in short stature children. Panminerva medica. 2023;65(3):432-433. PMID: 34060279.
  41. 46Crabbé R, et al. Recombinant human growth hormone for children born small for gestational age: meta-analysis confirms the consistent dose-effect relationship on catch-up growth. Journal of endocrinological investigation. 2008;31(4):346-51. PMID: 18475054.
  42. 47Wolfgram PM, et al. Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome. Current opinion in pediatrics. 2013;25(4):509-14. PMID: 23782572.
  43. 48Lee SY, et al. Structural and functional characterization of recombinant human growth hormone isolated from transgenic pig milk. PloS one. 2020;15(7):e0236788. PMID: 32735629.
  44. 49Loftus J, et al. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin. Current medical research and opinion. 2024;40(2):175-184. PMID: 38053515.
  45. 50Cheng YH, et al. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2005;26(1):9-15. PMID: 15970435.
  46. 51Massart F, et al. Height outcome of the recombinant human growth hormone treatment in patients with SHOX gene haploinsufficiency: a meta-analysis. Pharmacogenomics. 2013;14(6):607-12. PMID: 23570464.
  47. 52Ahangari G, et al. Growth hormone antibodies formation in patients treated with recombinant human growth hormone. International journal of immunopathology and pharmacology. 2004;17(1):33-8. PMID: 15000864.
  48. 53Massart F, et al. Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics. 2015;16(17):1965-73. PMID: 26555758.
  49. 54Zhu F, et al. Construction and evaluation of a height prediction model for children with growth disorders treated with recombinant human growth hormone. BMC endocrine disorders. 2025;25(1):170. PMID: 40634928.
  50. 55Pichard C, et al. Recombinant human growth hormone in chronic and acute respiratory insufficiency. Hormone research. 1996;46(4-5):222-9. PMID: 8950625.
  51. 56Losada F, et al. Effects of human recombinant growth hormone on donor-site healing in burned adults. World journal of surgery. 2002;26(1):2-8. PMID: 11898025.
  52. 57López-Siguero JP, et al. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. Drug design, development and therapy. 2017;11:1489-1495. PMID: 28553079.
  53. 58Keating GM, et al. Somatropin (Zorbtive): in short bowel syndrome. Drugs. 2004;64(12):1375-81; discussion 1382-3. PMID: 15200350.
  54. 59Houdijk EC, et al. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta paediatrica (Oslo, Norway : 1992). 1997;86(12):1301-7. PMID: 9475305.
  55. 60Maniatis AK, et al. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial. Hormone research in paediatrics. 2022;95(3):233-243. PMID: 35263755.
The HGH (Somatotropin) Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →